

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

ceritinib (Zykadia)

Notes:

- Quantity Limits: Yes
- ^ Adequate trial is defined as treatment duration of at least 21 days
- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Initiation (new start) criteria: Non-formulary **ceritinib (Zykadia)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by a hematologist or oncologist
 - Age greater than or equal to 18 years
 - Patient has a diagnosis of metastatic non-small cell lung cancer
 - Molecular profiling with anaplastic lymphoma kinase (ALK) gene rearrangement and meets all of the following:
 - The patient has failed an adequate trial[^] of alectinib due to diffuse progression or patient has an allergy or intolerance* to alectinib
 - The patient has failed an adequate trial[^] of second-line lorlatinib due to diffuse progression or patient has an allergy or intolerance* to lorlatinib
- OR-**
- Molecular profiling with ROS1 Rearrangement - AND - patient has failed an adequate trial[^] of entrectinib or patient has an allergy or intolerance* to entrectinib

Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously: Non-formulary **ceritinib (Zykadia)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by a hematologist or oncologist
 - Age greater than or equal to 18 years
 - Patient has a diagnosis of metastatic non-small cell lung cancer
 - Molecular profiling with anaplastic lymphoma kinase (ALK) gene rearrangement
- OR-**
- Molecular profiling with ROS1 rearrangement

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary **ceritinib (Zykadia)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by a hematologist or oncologist
- Age greater than or equal to 18 years

kp.org

Revised: 04/13/23
Effective: 06/15/23

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest

Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

ceritinib (Zykadia)

- Patient has a diagnosis of metastatic non-small cell lung cancer
- Molecular profiling with anaplastic lymphoma kinase (ALK) gene rearrangement
- OR-**
- Molecular profiling with ROS1 rearrangement

kp.org

Revised: 04/13/23
Effective: 06/15/23

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest